蛋白质精氨酸残基化学修饰酶PADs与PRMTs在人肝癌细胞系中的表达

doi:10.16352/j.issn.1001-6325.2023.06.0898

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (6): 898-903.doi: 10.16352/j.issn.1001-6325.2023.06.0898

蛋白质精氨酸残基化学修饰酶PADs与PRMTs在人肝癌细胞系中的表达

邹瑾¹, 何向蕾^1,2, 张欣^1,2, 陈日萍¹, 张宇¹, 胡帅悦¹, 应士波^1*

1.杭州医学院公共卫生学院,浙江杭州 310012;
2.浙江省人民医院杭州医学院附属人民医院,浙江杭州 310011

收稿日期:2023-01-14 修回日期:2023-03-29 出版日期:2023-06-05 发布日期:2023-05-31
通讯作者: ^*shiboying@hmc.edu.cn
基金资助:
国家自然科学基金(81973011);浙江省基础公益研究计划(LGF21H260010);国家级大学生创新创业训练计划(202213023010)

Expression of chemical modification enzymes PADs and PRMTs targeting protein arginine residues in human hepatocellular carcinoma cell lines

ZOU Jin¹, HE Xianglei^1,2, ZHANG Xin^1,2, CHEN Riping¹, ZHANG Yu¹, HU Shuaiyue¹, YING Shibo^1*

1. School of Public Health, Hangzhou Medical College, Hangzhou 310012;
2. People's Hospital of Hangzhou Medical College, Zhejiang Provincial People's Hospital, Hangzhou 310011, China

Received:2023-01-14 Revised:2023-03-29 Online:2023-06-05 Published:2023-05-31
Contact: ^*shiboying@hmc.edu.cn

摘要/Abstract

摘要： 目的探究蛋白质精氨酸脱亚胺酶(PADs)和蛋白质精氨酸甲基转移酶(PRMTs)在肝癌细胞系中的表达水平,并分析PADs催化的蛋白瓜氨酸化水平是否与PRMTs表达有关。方法通过RT-qPCR检测肝癌细胞系中PADs和PRMTs的mRNA转录水平,Western blot检测PADs、瓜氨酸化蛋白和PRMTs蛋白表达水平。利用生物信息学分析TCGA数据库中肝癌组织PADs和PRMTs的mRNA相关性,免疫组化检测肝癌组织PADs、瓜氨酸化蛋白和PRMTs表达。结果与正常肝细胞LX-2相比,PAD2和PRMT1在Huh7细胞中mRNA转录水平升高(P＜0.001),PAD4、PRMT1、PRMT5和PRMT7在HepG2细胞中mRNA转录水平升高(P＜0.01)。PAD2和PAD4在HepG2和Huh7中的蛋白水平显著高于LX-2(P＜0.01)。瓜氨酸化蛋白在HepG2和Huh7中的水平低于LX-2。肝癌组织中PADs和PRMTs的表达强于癌旁组织,但瓜氨酸化蛋白几乎呈阴性。PAD2和所有PRMTs家族成员在临床大样本中呈显著正相关性(P＜0.05)。结论肝癌细胞中PADs有较高的表达水平,而PADs催化的蛋白瓜氨酸化水平较低,可能是受胞内高水平表达的PRMTs酶竞争性影响。

关键词: 肝细胞癌, 蛋白质精氨酸脱氨酶, 瓜氨酸化, 蛋白质精氨酸甲基转移酶

Abstract: Objective To explore the expression of protein arginine deiminases (PADs) and protein arginine methyltransferases (PRMTs) in hepatocellular carcinoma, and to analyze whether the level of protein citrullination catalyzed by PADs is related to the expression of PRMTs. Methods The mRNA transcription of PADs and PRMTs in hepatoma cells was detected by quantitative PCR and the protein expression of PADs, citrullinated proteins and PRMTs was detected by Western blot. The mRNA correlation between PADs and PRMTs in liver cancer tissues in TCGA database was analyzed by bioinformatics, and the expressions of PADs, citrullinated proteins and PRMTs in liver cancer tissues was detected by immunohistochemistry. Results Compared with normal liver cell LX-2, the mRNA transcription of PAD2 and PRMT1 in Huh7 cells was higher (P＜0.001), and that of PAD4, PRMT1, PRMT5 and PRMT7 in HepG2 cells was higher (P＜0.01). The protein level of PAD2 and PAD4 in HepG2 and Huh7 was significantly higher than those in LX-2 (P＜0.01). The expression level of citrullinated protein in HepG2 and Huh7 was lower than that in LX-2. The expression of PADs and PRMTs in hepatocellular carcinoma was stronger than that in adjacent tissues, and the expression of citrullinated proteins was almost negative. There were positive correlation between PAD2 and all PRMTs in clinical sample database (P＜0.05). Conclusions The expression of PADs is high in hepatocellular carcinoma, whereas the expression of citrullinated proteins is low, which may be affected by the competition of PRMTs enzyme highly expressed in cells.

Key words: hepatocellular carcinoma, protein arginine deiminases, citrullination, protein arginine methyltransferases

中图分类号:

邹瑾, 何向蕾, 张欣, 陈日萍, 张宇, 胡帅悦, 应士波. 蛋白质精氨酸残基化学修饰酶PADs与PRMTs在人肝癌细胞系中的表达[J]. 基础医学与临床, 2023, 43(6): 898-903.

ZOU Jin, HE Xianglei, ZHANG Xin, CHEN Riping, ZHANG Yu, HU Shuaiyue, YING Shibo. Expression of chemical modification enzymes PADs and PRMTs targeting protein arginine residues in human hepatocellular carcinoma cell lines[J]. Basic & Clinical Medicine, 2023, 43(6): 898-903.

参考文献 12

[1]	Llovet JM, Kelley RK, Villanueva A, et al. Hepato-cellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7:6. doi: 10.1038/s41572-020-00240-3.
[2]	McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma[J]. Hepatology, 2021, 73: 4-13.
[3]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71: 209-249.
[4]	Mondal S, Thompson PR. Protein arginine deiminases (PADs): biochemistry and chemical biology of protein citrullination[J]. Acc Chem Res, 2019, 52: 818-832.
[5]	Wang YB, Chen RP, Gan YH, et al. The roles of PAD2- and PAD4-mediated protein citrullination catalysis in cancers[J]. Int J Cancer, 2021, 148: 267-276.
[6]	Lei Y, Han P, Tian D. Protein arginine methyltrans-ferases and hepatocellular carcinoma: A review[J]. Transl Oncol, 2021, 14: 101194.doi:10.1016/j.tranon.2021.101194.
[7]	Guccione E, Richard S. The regulation, functions and clinical relevance of arginine methylation[J]. Nat Rev Mol Cell Biol, 2019, 20: 642-657.
[8]	林群, 刘丽铭, 代辉, 等. 三阴性乳腺癌细胞系MDA-MB-231中PRMT1通过C/EBPα调控c-myc表达[J].基础医学与临床, 2019, 39: 949-953.
[9]	Nault JC, Villanueva A. Biomarkers for hepatobiliary cancers[J]. Hepatology, 2021, 73 Suppl 1: 115-127.
[10]	Guo W, Zheng YB, Xu B, et al. Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors[J]. Onco Targets Ther, 2017, 10: 1475-1485.
[11]	van der Windt DJ, Sud V, Zhang H, et al. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis[J]. Hepatology, 2018, 68: 1347-1360.
[12]	Clancy KW, Russell AM, Subramanian V, et al. Citrullination/Methylation crosstalk on histone H3 regulates ER-target gene transcription[J]. ACS Chem Biol, 2017, 12: 1691-1702.

[1]	依马木买买提江·阿布拉, 帕哈尔丁·白克热, 易超, 佟庆. 血浆hsa_circ_005230在原发性肝细胞癌诊断和预后评估中的临床价值[J]. 基础医学与临床, 2023, 43(9): 1417-1422.
[2]	林映雪, 崔海鹏, 王爱国, 姚银辉, 赵娟. 雷帕霉素减缓转基因小鼠肝细胞癌进展[J]. 基础医学与临床, 2023, 43(8): 1241-1246.
[3]	干译涵, 沈蔚, 陈伊童, 严凯丽, 胡帅悦, 蒋兆强, 应士波. 蛋白质精氨酸脱亚胺酶2与4在恶性间皮瘤中的表达及其临床意义[J]. 基础医学与临床, 2023, 43(7): 1117-1121.
[4]	冀梦蝶, 苑赞, 卞晓翠, 杨玉容, 郭鑫, 王琦, 陈阳. 人肝癌细胞系HepG2和Huh7中的基因组拷贝数变异分析[J]. 基础医学与临床, 2023, 43(6): 960-966.
[5]	刘爱霞, 张浩, 孙杰, 杨丽华, 赵晓涛. GPS2对肝癌细胞系MHCC-97H增殖、迁移与侵袭的调控作用[J]. 基础医学与临床, 2023, 43(12): 1784-1791.
[6]	查娜, 郝丹丹, 李天柱. microRNAs通过Hippo通路抑制肝细胞癌发生的研究进展[J]. 基础医学与临床, 2023, 43(12): 1871-1875.
[7]	黄驿胜, 叶启文, 王竞枫. miR-203a-3p抑制人肝癌细胞系增殖[J]. 基础医学与临床, 2023, 43(1): 87-94.
[8]	赵钰珊, 冀梦蝶, 董昱诚, 郭鑫, 宋博渊, 陈阳. 肝细胞癌中EZH2基因相关的表观遗传调控机制[J]. 基础医学与临床, 2022, 42(6): 864-870.
[9]	王玉敏, 陈济超, 王洪权, 王金华, 唐博. MicroRNAs靶向脂代谢重编程参与肝细胞癌发生的研究进展[J]. 基础医学与临床, 2022, 42(12): 1930-1934.
[10]	吴娜, 王东, 白咸勇. 细胞自噬与肝细胞癌的研究进展[J]. 基础医学与临床, 2021, 41(10): 1514-1517.
[11]	倪安妮, 梁清洋, 姚鸿飞, 李根亮, 唐玉莲. 花生四烯酸代谢基因对小鼠肝细胞癌中环氧化酶P450途径的影响[J]. 基础医学与临床, 2020, 40(8): 1053-1058.
[12]	曹明月, 李高翔, 陈昱竹, 黄薇, 杨楠, 刘雁勇. 儿茶酚胺类应激激素促进小鼠肝癌细胞系H22中G₀期细胞周期再入[J]. 基础医学与临床, 2020, 40(7): 897-902.
[13]	刘娜斯, 曹明月, 吴友明, 黄薇, 杨楠, 刘雁勇. HSP90抑制剂抑制糖酵解并促进小鼠肝癌细胞系H22凋亡[J]. 基础医学与临床, 2020, 40(7): 912-916.
[14]	张新然, 张弋, 高慧儿, 强兆艳, 李咏梅. Shc3高表达抑制人肝癌细胞系凋亡并参与肝癌耐药[J]. 基础医学与临床, 2020, 40(4): 473-478.
[15]	黄海良, 丁伟伟, 李冬雪. CRNDE过表达促进人肝癌细胞系HepG2增殖和迁移[J]. 基础医学与临床, 2020, 40(2): 219-223.

蛋白质精氨酸残基化学修饰酶PADs与PRMTs在人肝癌细胞系中的表达

Expression of chemical modification enzymes PADs and PRMTs targeting protein arginine residues in human hepatocellular carcinoma cell lines

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 12

相关文章 15

编辑推荐

Metrics

本文评价